Clinical Trials
Pancreatic Cancer Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Recombinant Fusion Proteins, Small Molecule, Monoclonal Antibody, Peptide, Polymer, Gene Therapy; By Treatment Type: Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others; Drug Profile; Key Players
According to World Cancer Research Fund International, pancreatic cancer is one of the most common cancer globally. The treatment options for pancreatic cancer depend on the location and stage of the disease. Major companies and research institutes are working towards developing innovative treatments for pancreatic cancer treatment including development of combination drugs (stereotactic body radiotherapy (SBRT)), among others.
Report Coverage
Pancreatic Cancer Drug Pipeline report by Expert Market Research gives comprehensive insights on the pancreatic cancer drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. Moreover, the analysis based on efficacy and safety measures outcomes published for the trials will be covered including their adverse effects in pancreatic cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to pancreatic cancer are covered.
Pancreatic Cancer Drug Pipeline Outlook
Pancreatic cancer is among the most challenging cancer to treat, due to its typical late-stage diagnosis and aggressive nature. Due to the availability of limited effective treatment, there is a high need for the development of innovative therapies to provide effective treatment outcomes. According to American Cancer Society, average lifetime risk of pancreatic cancer is about 1 in 60 in women and 1 in 56 in men. There are two types of pancreatic cancer - pancreatic adenocarcinoma and pancreatic neuroendocrine tumors (nets). The symptoms include jaundice (yellowing of the skin and eyes), unexplained weight loss, digestive issues such as vomiting, nausea among others. The report covers the pathophysiology and epidemiology of pancreatic cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment of pancreatic cancer in detail.
The treatment options for pancreatic cancer include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. The chemotherapy treatment includes adjuvant chemotherapy, neoadjuvant chemotherapy, and palliative chemotherapy. Common chemotherapy drugs include gemcitabine, capecitabine, irinotecan and leucovorin among others. The ongoing research on clinical trials aim to identify efficient therapeutic targets, development of novel therapies which are showing promising for the treatment of pancreatic cancer.
For instance, George Fisher, MD, PhD, Stanford University, collaborated for clinical trial of immunotherapy drug Keytruda (pembrolizumab) for the treatment of pancreatic tumors which have genetic mutation called a mismatch repair defect. This trial has resulted into the FDA approval for the drug. Another ongoing trial at Stanford University is being conducted for 'in-situ vaccines’ which aims to investigate injecting tiny amounts of immune-stimulating agents into solid tumors directly.
Pancreatic Cancer Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of pancreatic cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analysis based on phase.
- Late-Stage Products (Phase III and Phase IV)
- Mid-Stage Products (Phase II)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analysis based on route of administration.
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Others
Pancreatic Cancer Drug Pipeline Analysis by Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs for pancreatic cancer. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, majority of the ongoing clinical trials for pancreatic cancer are currently in Phase II of their development.
University of Texas Southwestern Medical Center is conducting a clinical trial for Pioglitazon e to determine whether addition of the pioglitazone oral medication to standard chemotherapy treatment results in improvement of blood tests.
Pancreatic Cancer – Drug Pipeline Analysis by Route of Administration
The route of administration categories covered under pancreatic cancer pipeline analysis include oral, intravenous, subcutaneous, parenteral and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials of pancreatic cancer. According to EMR analysis, the oral route accounted for major share of pancreatic cancer clinical trials.
Pancreatic Cancer Drug Pipeline Competitive Dynamics
The EMR report for pancreatic cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of few players involved in pancreatic cancer clinical trials –
- Pfizer Inc.
- Sanofi SA
- Novartis Pharmaceuticals
- Bristol-Myers Squibb
- Eisai Inc.
- AstraZeneca Plc
- GlaxoSmithKline
- F-Hoffmann-La Roche AG
- Others
Pancreatic Cancer Pipeline Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for pancreatic cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
Drug: Exenatide – AstraZeneca
Exenatide is currently under observational phase sponsored by AstraZeneca. The study is being done to assess the risk of developing pancreatic cancer who have initiated exenatide among type 2 diabetes mellitus (T2DM) patients.
Drug: Sunitinib Malate- Pfizer
Sunitinib malate is currently under phase III clinical trials, sponsored by Pfizer. The purpose of the study is to assess the efficiency of sunitinib in patients suffering from advanced pancreatic islet cell tumors. The study will determine the status and size of their tumors, survival, quality of life and safety of the drug.
Monoclonal Antibody - Hoffmann-La Roche
Monoclonal Antibody trials is currently under phase I clinical trials, developed by Hoffmann-La Roche. The study is being conducted to assess whether the activation of certain immune system cells will be safe and well tolerated in combination with cytotoxic chemotherapy.
Drug: Leucovorin – Sanofi
The study is being conducted to identify whether the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival for pancreatic cancer. This drug is currently under phase III clinical trial, being developed by Sanofi.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration Oral |
|
| Drug Classes |
|
| Treatment Type |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Key Questions Answered in the Pancreatic Cancer – Pipeline Analysis Report
- What is the current landscape of pancreatic cancer pipeline drugs?
- How many companies are developing pancreatic cancer drugs?
- How many phase III and phase IV drugs are currently present in pancreatic cancer pipeline drugs?
- Which companies/institutions are leading the pancreatic cancer drug development?
- In which phase, the drugs are mostly present in pancreatic cancer pipeline currently?
- What is efficacy and safety profiles of pancreatic cancer pipeline drugs?
- What are the opportunities and challenges present in pancreatic cancer clinical pipeline landscape?
- Which company is conducting the major trials for pancreatic cancer drugs?
- What are the geographies covered for clinical trials in pancreatic cancer?
- What are the clinical trial results of the drugs under development for pancreatic cancer?
- What are emerging trends in pancreatic cancer clinical trials?
RELATED REPORTS
Global Cancer Supportive Care Drugs Market
Global Cancer Therapeutics Market
Global Cancer Immunotherapy Market
Global Recombinant Protein Market
Global Monoclonal Antibodies Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Pancreatic Cancer
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Pancreatic Cancer
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Pancreatic Cancer: Epidemiology Snapshot
5.1 Pancreatic Cancer Incidence by Key Markets
5.2 Pancreatic Cancer – Patients Seeking Treatment in Key Markets
6 Pancreatic Cancer: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Pancreatic Cancer: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Pancreatic Cancer, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Pancreatic Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Pancreatic Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Gemcitabine
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Leucovorin
10.2.3 Larotaxel
10.2.4 Oxaliplatin
10.2.5 Other Drugs
11 Pancreatic Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Enzastaurin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Gemcitabine
11.2.3 Other Drugs
12 Pancreatic Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 MVT-2163
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 LY2157299
12.2.3 Other Drugs
13 Pancreatic Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Bethanechol
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Pembrolizumab
13.2.3 Other Drugs
14 Pancreatic Cancer, Key Drug Pipeline Companies
14.1 Pfizer, Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Sanofi SA
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Novartis Pharmaceuticals
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Bristol-Myers Squibb
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Eisai Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 AstraZeneca Plc
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 GlaxoSmithKline
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
Purchase Options
Call us
Purchase Full Report
Datasheet
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2499
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3499
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4499
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER